NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Price Target & More

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc. (NASDAQ:PTI) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.72) by $0.16. The firm earned $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 105.53% and a negative net margin of 1,112.75%. View Proteostasis Therapeutics' Earnings History.

4 Wall Street analysts have issued 1 year target prices for Proteostasis Therapeutics' shares. Their predictions range from $8.00 to $25.00. On average, they expect Proteostasis Therapeutics' share price to reach $14.75 in the next year. View Analyst Ratings for Proteostasis Therapeutics.

Proteostasis Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 3,189,620 shares, an increase of 249.8% from the February 28th total of 911,789 shares. Based on an average trading volume of 6,362,351 shares, the days-to-cover ratio is currently 0.5 days. Approximately 14.6% of the shares of the company are short sold.

Some companies that are related to Proteostasis Therapeutics include Strongbridge Biopharma (SBBP), Catalyst Biosciences (CBIO), Merus (MRUS), Kadmon (KDMN), Durect (DRRX), Seres Therapeutics (MCRB), BioSpecifics Technologies (BSTC), AVEO Pharmaceuticals (AVEO), Celyad (CYAD), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Minerva Neurosciences (NERV), Syndax Pharmaceuticals (SNDX) and Kindred Biosciences (KIN).

(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

News headlines about PTI stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a news sentiment score of 0.07 on Accern's scale. They also assigned news stories about the company an impact score of 45.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $5.12.

Proteostasis Therapeutics has a market capitalization of $174.83 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.

Proteostasis Therapeutics' mailing address is 200 TECHNOLOGY SQUARE 4th FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-225-0096 or via email at [email protected]